Reindeer

Statement - Federal government concerned about further delays in release of Quebec government's caribou strategy

Retrieved on: 
星期二, 四月 30, 2024

"I would like to thank the Government of Quebec for presenting their plans before the May 1 deadline.

Key Points: 
  • "I would like to thank the Government of Quebec for presenting their plans before the May 1 deadline.
  • The Government of Quebec must publish a strategy for all Boreal Caribou populations in Quebec, including immediate interim measures.
  • We remain open to supporting the Government of Quebec in implementing measures to restore and protect the Boreal and Gaspé Caribou.
  • We look forward to working with the Government of Quebec and Indigenous peoples to make this happen."

The Founders Arena Unveils Startups Participating in Second Annual WealthTech Accelerator

Retrieved on: 
星期一, 四月 22, 2024

ARLINGTON, Texas, April 22, 2024 (GLOBE NEWSWIRE) -- The Founders Arena WealthTech Accelerator, in collaboration with First Rate, Inc., SEI®, Republic Capital Group, the City of Arlington and the Arlington Economic Development Corporation, are announcing the selection of the next cohort of companies that will be joining its second global accelerator program beginning today.

Key Points: 
  • Echoing the accelerator's unique position, Pamela Cytron, President of The Founders Arena, states, “Our second cohort represents the forefront of WealthTech innovation, with solutions that promise to reshape the industry's future.
  • Beginning today in Arlington, Texas, the 12-week accelerator program is designed to propel early- to growth-stage WealthTech founders in scaling their revenue and go-to-market efforts.
  • “The Founders Arena WealthTech Accelerator has brought tremendous innovation and economic vitality to Arlington.
  • “Republic Capital Group is excited to join as an official partner of The Founders Arena WealthTech Accelerator.

LG LAUNCHES VULNERABLE & ENDANGERED SPECIES AWARENESS CAMPAIGN IN TIMES SQUARE

Retrieved on: 
星期二, 四月 16, 2024

NEW YORK, April 16, 2024 /PRNewswire/ -- Heralding the arrival of Earth Day 2024, LG Electronics, unveiled today a 3D anamorphic experience on its Times Square billboard in New York City highlighting vulnerable and endangered species.  The LG Endangered Species Series, which will run throughout 2024, features partnerships with Discovery Education and the National Wildlife Federation focused on educating students K-12 on conservation initiatives.

Key Points: 
  • The LG Endangered Species Series, which will run throughout 2024, features partnerships with Discovery Education and the National Wildlife Federation focused on educating students K-12 on conservation initiatives.
  • Unveiling on its dynamic Times Square billboard, LG Electronics will introduce a digital out-of-home (OOH) campaign showcasing anamorphic content that will highlight some of the world's most vulnerable and endangered as well as recovered species in need of ongoing protection.
  • Through partnerships with global edtech leader Discovery Education and the National Wildlife Federation, LG will host a K-12 educational series about vulnerable and endangered species tied to the Time Square billboard.
  • The LG Endangered Species Series will provide K-12 students with a deeper understanding of the unique qualities of endangered animals, and the role they play in maintaining a healthy ecosystem while fostering an appreciation of what makes each species special.

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Retrieved on: 
星期四, 四月 4, 2024

BERKELEY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.

Key Points: 
  • The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.
  • CB-010 targets CD19, a protein on the surface of B cells, and has a PD-1 knockout (KO) that reduces CAR-T cell exhaustion.
  • CB-010 holds the potential for deep depletion of disease-causing B cells which could reset the immune system, leading to sustained drug-free remission.
  • Instead, the chRDNA technology allows for precise insertion of the CAR at an intended location within the T cell genome.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
星期三, 三月 27, 2024

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.

RegCell Appoints Leading T-Cell Therapy Expert Steven B. Kanner, Ph.D., to Board of Directors

Retrieved on: 
星期三, 四月 3, 2024

"We are honored to have Steve Kanner join our Board of Directors," remarked Professor Shimon Sakaguchi, co-founder of RegCell.

Key Points: 
  • "We are honored to have Steve Kanner join our Board of Directors," remarked Professor Shimon Sakaguchi, co-founder of RegCell.
  • "Dr. Kanner's profound understanding of immunology comes at a pivotal juncture for RegCell as we advance our clinical development and expand our Precision Epigenetic Reprogramming Platform.
  • Backed by leading institutional and corporate investors hailing from Japan, RegCell emerges as the next-generation global life science enterprise at the forefront of regulatory T-cell therapies.
  • Central to RegCell's innovation is its 'Precision Epigenetic Reprogramming' platform, which entails the epigenetic reprogramming of CD4+ T-cells into regulatory T-cells.

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

Retrieved on: 
星期一, 三月 25, 2024

SAN DIEGO, March 25, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024.

Key Points: 
  • SAN DIEGO, March 25, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024.
  • "Syed brings to Poseida an impressive combination of industry leadership and highly specialized drug development experience in cell therapy, and I am excited to welcome him to our leadership team during this important period of execution across our clinical stage CAR-T portfolio," said Kristin Yarema, Ph.D., President and Chief Executive Officer of Poseida.
  • Dr. Rizvi most recently served as Chief Medical Officer of Caribou Biosciences, where he was responsible for overall strategy and execution of all clinical development programs.
  • Prior to joining Caribou, he served as Chief Medical Officer at Chimeric Therapeutics, where he helped build the company's pipeline by licensing programs from leading universities and progressing existing programs through the clinical development process.

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
星期一, 三月 11, 2024

BERKELEY, Calif., March 11, 2024 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the fourth quarter and full year 2023 and reviewed recent pipeline progress.

Key Points: 
  • “For our lead program, CB-010, we plan to present initial dose expansion data and the RP2D in the second quarter of 2024.
  • For our third program, CB-012, we are thrilled to have recently dosed the first patient in the AMpLify trial.
  • In December 2023, Caribou shared regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B clinical meeting.
  • CB-012: Caribou plans to provide updates on dose escalation as the AMpLify Phase 1 clinical trial in r/r AML advances.

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences

Retrieved on: 
星期二, 二月 20, 2024

This approach is proprietary to Precision and results in T cells suitable for allogeneic use.

Key Points: 
  • This approach is proprietary to Precision and results in T cells suitable for allogeneic use.
  • Under the terms of the agreement, Precision will receive an upfront payment and, upon commercialization by Caribou, royalties on net sales of licensed products.
  • In addition, for each occurrence of certain strategic transactions involving Caribou, Precision is eligible to receive a specific tiered milestone payment.
  • This patent family is potentially also available for non-exclusive license to other high-quality partners in the cell therapy space.

Chronic wasting disease has been detected in British Columbia deer, and we need to act now

Retrieved on: 
星期五, 二月 16, 2024

Since 1996, a deadly neurodegenerative disease of cervids (deer, elk, moose, caribou, reindeer) has been spreading across Canada.

Key Points: 
  • Since 1996, a deadly neurodegenerative disease of cervids (deer, elk, moose, caribou, reindeer) has been spreading across Canada.
  • On Jan. 31, 2024, chronic wasting disease (CWD) was detected for the first time in British Columbia in two deer.

Disease-causing proteins

  • The protein is similar to other normal proteins in the body, except it’s abnormally shaped.
  • The abnormal folding of these disease-causing prion proteins — which are found most abundantly in the brain — leads to brain damage that makes the brain appear like a sponge.
  • Other TSEs include Creutzfeldt-Jakob disease in people, bovine-spongiform encephalopathy (“mad cow disease”) in cows, and scrapie in sheep and goats.
  • This means that early detection and management is critical for reducing the impact of this disease.

British Columbia’s preparations

  • has established a surveillance program to detect CWD as soon as possible.
  • Our research suggests that a robust approach to such a difficult disease will require rapid, collective and collaborative action across sectors.
  • This approach must involve wildlife managers, hunters, local communities, First Nations and researchers to integrate a number of approaches.

Surveillance and management

  • Many CWD management programs rely on removing infected animals from the landscape.
  • While it is mandatory to submit the heads from hunted cervids in select management units in B.C., in most regions, submission is voluntary.
  • Hunters can participate in CWD management and surveillance by removing the head of the animal and submitting it to a local testing station or freezer for CWD testing.
  • The public can also participate in CWD surveillance and management by reporting signs of sick animals and vehicle collisions with cervids.
  • This is why testing cervids that have been killed by vehicles is also a critical component of CWD surveillance and management.

Curbing the spread

  • CWD can spread between animals through contact with bodily fluids.
  • Legal restrictions on carcass transport and the use of urine-based scents in hunting can also reduce the unintentional spread of CWD.
  • Research has shown that community-focused communication and engagement are essential for the success of CWD management efforts.
  • In the days ahead, fostering open dialogue and collaboration will be paramount towards an effective and sustainable effort against CWD.


Kaylee Byers is the Regional Deputy Director of the British Columbia Node of the Canadian Wildlife Health Cooperative and collaborates with the Wildlife Health Program, which leads Chronic Wasting Disease surveillance in British Columbia. Sarah Robinson does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.